bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 1 from Microtubule Dynamics Control Tail Retraction in Migrating Vascular Endothelial Cells
Authors: Ganguly Anutosh , Yang Hailing , Zhang Hong , Cabral Fernando , Patel Kamala D.
Published: April 2023

PDF file - 94K, Supplementary figure 1. Structures of drugs used in these studies.
Supplementary Figure 5 from Redirecting Apoptosis to Aponecrosis Induces Selective Cytotoxicity to Pancreatic Cancer Cells through Increased ROS, Decline in ATP Levels, and VDAC
Authors: Dinnen Richard D. , Mao Yuehua , Qiu Wanglong , Cassai Nicholas , Slavkovich Vesna N. , Nichols Gwen , Su Gloria H. , Brandt-Rauf Paul , Fine Robert L.
Published: April 2023

PDF - 359KB, Supplementary Figure 5: Accumulation of intracellular O2 .- radicals in PANC-1 and MIA-PACA cells treated with AAA. A, B, Intracellular accumulation of O2.-radical in PANC-1 A, or MIA-PACA-2 B, cell lines +/-ATO, AA, or DSF using DHE. C, AAA-treated PANC-1 cells +/- 3.5 mM NAC, as measured by DHE.
Supplementary Figure Legends from Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma
Authors: Mirzoeva Olga K. , Collisson Eric A. , Schaefer Peter M. , Hann Byron , Hom Yun K. , Ko Andrew H. , Korn W. Michael
Published: April 2023

PDF - 47K, Legends for Supplementary Figures 1-3.
Supplementary Figure 3 from Redirecting Apoptosis to Aponecrosis Induces Selective Cytotoxicity to Pancreatic Cancer Cells through Increased ROS, Decline in ATP Levels, and VDAC
Authors: Dinnen Richard D. , Mao Yuehua , Qiu Wanglong , Cassai Nicholas , Slavkovich Vesna N. , Nichols Gwen , Su Gloria H. , Brandt-Rauf Paul , Fine Robert L.
Published: April 2023

PDF - 1108 KB, Supplementary Figure 3: A, Flow cytometric analysis for apoptosis/necrosis. MIA PaCa-2 cells +/- AAA, or PAC (25 μM) for 24h, and stained with Anx V/ PI. Apoptosis = Anx+/PI- (bottom right of each panel); Necrosis= Anx+/PI+ cells (top right of each panel). B, Confocal microscopy using Mitotracker Red followed by anti-AIF antibody (top row), or anti-Cytochrome C antibody (bottom row). The appearance of additional red and green staining in the AAA-treated cells (24h), cytochrome C panel as compared to control, demonstrates Cytochrome C was released from mitochondria in these cells. PAC concentration was 50 nM, for 24h. C, Intracellular reduced glutathione levels in MIA PaCa-2 cells after 4h of AAA treatment.
Supplementary Figure Legend from The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models
Authors: Smyth Tomoko , Van Looy Thomas , Curry Jayne E. , Rodriguez-Lopez Ana M. , Wozniak Agnieszka , Zhu Meijun , Donsky Rachel , Morgan Jennifer G. , Mayeda Mark , Fletcher Jonathan A. , Schöffski Patrick , Lyons John , Thompson Neil T. , Wallis Nicola G.
Published: April 2023

PDF file, 70KB.
Supplementary Figure 1 from The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models
Authors: Smyth Tomoko , Van Looy Thomas , Curry Jayne E. , Rodriguez-Lopez Ana M. , Wozniak Agnieszka , Zhu Meijun , Donsky Rachel , Morgan Jennifer G. , Mayeda Mark , Fletcher Jonathan A. , Schöffski Patrick , Lyons John , Thompson Neil T. , Wallis Nicola G.
Published: April 2023

PDF file, 56KB, Graphs showing the typical dose response of GIST882, GIST430 and GIST48 cell lines to AT13387 and imatinib.
Supplementary Figure 2 from Reexpression of Tumor Suppressor, sFRP1, Leads to Antitumor Synergy of Combined HDAC and Methyltransferase Inhibitors in Chemoresistant Cancers
Authors: Cooper Simon J. , von Roemeling Christina A. , Kang Kylie H. , Marlow Laura A. , Grebe Stefan K. , Menefee Michael E. , Tun Han W. , Colon-Otero Gerardo , Perez Edith A. , Copland John A.
Published: April 2023

PDF file, 3984K, Methylation pattern sequencing analysis of the sFRP1 promoter.
Supplementary Figure 3 from The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma Cells
Authors: Sehdev Vikas , Peng DunFa , Soutto Mohammed , Washington M. Kay , Revetta Frank , Ecsedy Jeffrey , Zaika Alexander , Rau Tilman T. , Schneider-Stock Regine , Belkhiri Abbes , El-Rifai Wael
Published: April 2023

PDF file - 1.8MB, Effects of MLN8238 and CDDP on proliferation and apoptosis in vivo.
Supplementary Figure 1 from Reexpression of Tumor Suppressor, sFRP1, Leads to Antitumor Synergy of Combined HDAC and Methyltransferase Inhibitors in Chemoresistant Cancers
Authors: Cooper Simon J. , von Roemeling Christina A. , Kang Kylie H. , Marlow Laura A. , Grebe Stefan K. , Menefee Michael E. , Tun Han W. , Colon-Otero Gerardo , Perez Edith A. , Copland John A.
Published: April 2023

PDF file, 328K, Authentication of the VHL mutant (Exon 2 c.407T>C) KIJ265T clear cell renal cell carcinoma cell line.
Supplementary Figure 1 from The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma Cells
Authors: Sehdev Vikas , Peng DunFa , Soutto Mohammed , Washington M. Kay , Revetta Frank , Ecsedy Jeffrey , Zaika Alexander , Rau Tilman T. , Schneider-Stock Regine , Belkhiri Abbes , El-Rifai Wael
Published: April 2023

PDF file - 149K, AURKA expression levels in esophageal cell lines.
Supplementary Figure 1 from Dual HER/VEGF Receptor Targeting Inhibits In Vivo Ovarian Cancer Tumor Growth
Authors: Becker Marc A. , Farzan Thahir , Harrington Sean C. , Krempski James W. , Weroha S. John , Hou Xiaonan , Kalli Kimberly R. , Wong Tai W. , Haluska Paul
Published: April 2023

PDF - 32KB, No significant change in body weight was observed throughout the experimental duration.
Supplementary Figure Legend from Restoration of miR-200c to Ovarian Cancer Reduces Tumor Burden and Increases Sensitivity to Paclitaxel
Authors: Cittelly Diana M. , Dimitrova Irina , Howe Erin N. , Cochrane Dawn R. , Jean Annie , Spoelstra Nicole S. , Post Miriam D. , Lu Xian , Broaddus Russell R. , Spillman Monique A. , Richer Jennifer K.
Published: April 2023

PDF file - 100K
Supplementary Figure 3 from Restoration of miR-200c to Ovarian Cancer Reduces Tumor Burden and Increases Sensitivity to Paclitaxel
Authors: Cittelly Diana M. , Dimitrova Irina , Howe Erin N. , Cochrane Dawn R. , Jean Annie , Spoelstra Nicole S. , Post Miriam D. , Lu Xian , Broaddus Russell R. , Spillman Monique A. , Richer Jennifer K.
Published: April 2023

PDF file - 235K, Tumor burden at day 6, miR-200c levels and ZEB expression in tumors of mice treated with paclitaxel and miR-200c
Supplementary Figure 1 from The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants
Authors: Medová Michaela , Pochon Benoît , Streit Bruno , Blank-Liss Wieslawa , Francica Paola , Stroka Deborah , Keogh Adrian , Aebersold Daniel M. , Blaukat Andree , Bladt Friedhelm , Zimmer Yitzhak
Published: April 2023

PDF - 2667KB, Supplementary figure 1 - Impact of EMD1214063 treatment on the viability of NIH3T3 MET M1268T and Y1248H variants.
Supplementary Table 2 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder
Authors: Sutherland Mark , Gill Jason H. , Loadman Paul M. , Laye Jonathan P. , Sheldrake Helen M. , Illingworth Nicola A. , Alandas Mohammed N. , Cooper Patricia A. , Searcey Mark , Pors Klaus , Shnyder Steve D. , Patterson Laurence H.
Published: April 2023

PDF file - 52K, Lack of CYP1 induction by the chloromethylpyrroloindoline ICT2700
Supplementary Figure 2 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
Authors: Li Huifang , Hassona Mohamed D.H. , Lack Nathan A. , Axerio-Cilies Peter , Leblanc Eric , Tavassoli Peyman , Kanaan Natalia , Frewin Kate , Singh Kriti , Adomat Hans , Böhm Konrad J. , Prinz Helge , Guns Emma Tomlinson , Rennie Paul S. , Cherkasov Artem
Published: April 2023

PDF file, 109K, Inhibition of VPC-3022 against wild-type AR in HeLa-AR cells. HeLa-AR cells transfected with ARR3tk-luciferase reporter were treated with VPC-3022 for 24 hours in various concentrations in the presence of 0.1 nM R1881. Error bars indicate standard deviation.
Supplemental Figure 7 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
Authors: Blackwood Elizabeth , Epler Jennifer , Yen Ivana , Flagella Michael , O'Brien Tom , Evangelista Marie , Schmidt Stephen , Xiao Yang , Choi Jonathan , Kowanetz Kaska , Ramiscal Judi , Wong Kenton , Jakubiak Diana , Yee Sharon , Cain Gary , Gazzard Lewis , Williams Karen , Halladay Jason , Jackson Peter K. , Malek Shiva
Published: April 2023

GNE-900 is more potent at chemopotentiation in p53 null HCT-116.
Supplemental Figure 5 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
Authors: Blackwood Elizabeth , Epler Jennifer , Yen Ivana , Flagella Michael , O'Brien Tom , Evangelista Marie , Schmidt Stephen , Xiao Yang , Choi Jonathan , Kowanetz Kaska , Ramiscal Judi , Wong Kenton , Jakubiak Diana , Yee Sharon , Cain Gary , Gazzard Lewis , Williams Karen , Halladay Jason , Jackson Peter K. , Malek Shiva
Published: April 2023

Representative histograms from high content imaging studies.
Supplementary Methods and Figure Legends from Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer
Authors: Song Bing , Liu X. Shawn , Rice Steven J. , Kuang Shihuan , Elzey Bennett D. , Konieczny Stephen F. , Ratliff Timothy L. , Hazbun Tony , Chiorean Elena G. , Liu Xiaoqi
Published: April 2023

PDF file - 88K
Supplementary Figure 6 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Authors: Ortenberg Rona , Sapir Yair , Raz Lee , Hershkovitz Liat , Ben Arav Ayelet , Sapoznik Sivan , Barshack Iris , Avivi Camila , Berkun Yackov , Besser Michal J. , Ben-Moshe Tehila , Schachter Jacob , Markel Gal
Published: April 2023

PDF file, 39KB, Quantification of CEACAM1 molecules in normal cell strains and melanoma cell lines.
Supplementary Figure 1 from Tumor-Initiating Cells and FZD8 Play a Major Role in Drug Resistance in Triple-Negative Breast Cancer
Authors: Yin Shuping , Xu Liping , Bonfil R. Daniel , Banerjee Sanjeev , Sarkar Fazlul H. , Sethi Seema , Reddy Kaladhar B.
Published: April 2023

PDF file - 2379KB, Cisplatin plus TRAIL treatment increases c-myc expression in vitro and in vivo. Western blot analysis and corresponding densitometries in cell lines (A and B) and tumor xenografts (C and D) show consistent increase in c-myc protein levels after cisplatin plus TRAIL treatment.
Supplementary Figure 2 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Authors: Ortenberg Rona , Sapir Yair , Raz Lee , Hershkovitz Liat , Ben Arav Ayelet , Sapoznik Sivan , Barshack Iris , Avivi Camila , Berkun Yackov , Besser Michal J. , Ben-Moshe Tehila , Schachter Jacob , Markel Gal
Published: April 2023

PDF file, 32KB, Validation of the immune-protective effect of CEACAM1 in CEACAM1-silenced melanoma cells.
Supplementary Figures 1 - 7, Table 1 from Small-Molecule Inhibitors of Acetyltransferase p300 Identified by High-Throughput Screening Are Potent Anticancer Agents
Authors: Yang Heng , Pinello Christie E. , Luo Jian , Li Dawei , Wang Yunfei , Zhao Lisa Y. , Jahn Stephan C. , Saldanha Sanjay Adrian , Planck Jamie , Geary Kyla R. , Ma Haiching , Law Brian K. , Roush William R. , Hodder Peter , Liao Daiqing
Published: April 2023

PDF file - 456K, Table S1: Growth inhibition of NCI-60 panel of cancer cell lines by L002 (NSC764414); Supplemental Figure 1: Distribution of hits in the primary potentiator screen ; Supplemental Figure 2: Hit distribution in the primary and counterscreen assays ; Supplemental Figure 3: Fluorescence-based in vitro p300 inhibition assay ; Supplemental Figure 4: Summary of the HTS campaign ; Supplemental Figure 5: L002 does not inhibit HDACs ; Supplemental Figure 6: L002 does not inhibit HMTs ; Supplemental Figure 7: Impacts of L002 and other hits on histone modifications
Supplementary Figure 1 from Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites
Authors: Montano Ryan , Chung Injae , Garner Kristen M. , Parry David , Eastman Alan
Published: April 2023

PDF file - 21K
Supplementary Table 3 from MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma
Authors: Asundi Jyoti , Lacap Jennifer A. , Clark Suzanna , Nannini Michelle , Roth Leslie , Polakis Paul
Published: April 2023

PDF file - 55KB, normal tissue stats.
Supplementary Figure 4 from Human Umbilical Cord Blood–Derived Mesenchymal Stem Cells Producing IL15 Eradicate Established Pancreatic Tumor in Syngeneic Mice
Authors: Jing Wei , Chen Ying , Lu Lei , Hu Xiangui , Shao Chenghao , Zhang Yijie , Zhou Xuyu , Zhou Yingqi , Wu Lang , Liu Rui , Fan Kexing , Jin Gang
Published: April 2023

PDF - 101K, Intratumor infiltration of gammadelta T cells were determined by flow cytometry at 10 days after MSC-IL-15 injection. **, P<0.01.
Supplementary Figure 1 from Human Umbilical Cord Blood–Derived Mesenchymal Stem Cells Producing IL15 Eradicate Established Pancreatic Tumor in Syngeneic Mice
Authors: Jing Wei , Chen Ying , Lu Lei , Hu Xiangui , Shao Chenghao , Zhang Yijie , Zhou Xuyu , Zhou Yingqi , Wu Lang , Liu Rui , Fan Kexing , Jin Gang
Published: April 2023

PDF - 71K, The expression of immunologic markers on MSC surface by FACS analysis of CD14, CD11b, and CD16 expressions.
Supplementary Figure 6 from MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma
Authors: Asundi Jyoti , Lacap Jennifer A. , Clark Suzanna , Nannini Michelle , Roth Leslie , Polakis Paul
Published: April 2023

PDF file - 170KB, apoptosis data.
Supplementary Figure 3 from MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma
Authors: Asundi Jyoti , Lacap Jennifer A. , Clark Suzanna , Nannini Michelle , Roth Leslie , Polakis Paul
Published: April 2023

PDF file - 175KB, UACC257 efficacy.
Supplementary Figures 1 through 10 from V-ATPase Inhibition Regulates Anoikis Resistance and Metastasis of Cancer Cells
Authors: Schempp Christina M. , von Schwarzenberg Karin , Schreiner Laura , Kubisch Rebekka , Müller Rolf , Wagner Ernst , Vollmar Angelika M.
Published: April 2023

PDF - 300K, Figure S1A: Chemical structure of archazolid A; S1B: Alkalization of lysosomes by archazolid treatment; Figure S2A: T24 cells stimulated with archazolid for 24h show no sign of apoptosis; S2B: Concanamycin impairs colony formation in T24 cells; Figure S3: Adherent T24 cells stimulated with archazolid for 48h are highly apoptotic; Figure S4: 4T1 cells show no cell death induction after 24h archazolid treatment; Figure S5: BIM levels after archazolid treatment in MDA-MB-231 and MCF7 cells; Figure S6: Quantification of BIM rescue by proteasome inhibitors; Figure S7A: ROS induction in floating 4T1 cells; S7B: ROS levels of archazolid treated, floating cells reached ROS levels of untreated adherent cells; Figure S8: Phosphorylation of Akt and ERK is increased early after detachment but decreases again after 24h; Figure S9: The inhibitors LY-294002 (Akt), PD 98059 (ERK) or Saracatinib (c-Scr) induce apoptosis in floating cancer cells; Figure S10: Anoikis resistance and archazolid action on anoikis resistant cancer cells.
Supplementary Tables 1 through 3 from PP2A Inhibition Is a Common Event in Colorectal Cancer and Its Restoration Using FTY720 Shows Promising Therapeutic Potential
Authors: Cristóbal Ion , Manso Rebeca , Rincón Raúl , Caramés Cristina , Senin Clara , Borrero Aurea , Martínez-Useros Javier , Rodriguez María , Zazo Sandra , Aguilera Oscar , Madoz-Gúrpide Juan , Rojo Federico , García-Foncillas Jesús
Published: April 2023

PDF - 124K, Supplementary Table 1. Clinical and molecular characteristics of the 21 patients with CRC included in the study. Supplementary Table 2. Analysis of PP2A activity levels using 1D6 or FL-309 antibodies, SET overexpression, CIP2A overexpression, PPP2R2A downregulation and PPP2R5E downregulation in 21 CRC patients. Supplementary Table 3. Primer sequences used for PPP2R1B mutation analysis.
Supplementary Figure 4 from Pharmacologic Inhibition of MEK Signaling Prevents Growth of Canine Hemangiosarcoma
Authors: Andersen Nicholas J. , Nickoloff Brian J. , Dykema Karl J. , Boguslawski Elissa A. , Krivochenitser Roman I. , Froman Roe E. , Dawes Michelle J. , Baker Laurence H. , Thomas Dafydd G. , Kamstock Debra A. , Kitchell Barbara E. , Furge Kyle A. , Duesbery Nicholas S.
Published: April 2023

PDF file - 126K, Supplemental Figure S4. Increase in MEF2c IHC staining in AS and HSA primary tumors.
Supplementary Figure Legend from Polymorphic CAG Repeat and Protein Expression of Androgen Receptor Gene in Colorectal Cancer
Authors: Huang Rui , Wang Guiyu , Song Yanni , Wang Feng , Zhu Bing , Tang Qingchao , Liu Zheng , Chen Yinggang , Zhang Qian , Muhammad Shan , Wang Xishan
Published: April 2023

Supplementary Figure Legend
Supplementary Figure 1 from Pharmacologic Inhibition of MEK Signaling Prevents Growth of Canine Hemangiosarcoma
Authors: Andersen Nicholas J. , Nickoloff Brian J. , Dykema Karl J. , Boguslawski Elissa A. , Krivochenitser Roman I. , Froman Roe E. , Dawes Michelle J. , Baker Laurence H. , Thomas Dafydd G. , Kamstock Debra A. , Kitchell Barbara E. , Furge Kyle A. , Duesbery Nicholas S.
Published: April 2023

PDF file - 94K, Supplemental Figure S1. Sensitivity of HSA-derived visceral (VCT75), cutaneous (VCT115), and cardiac (VCT142) primary cells to CI-1040, sorafenib, and LY294002.
Supplementary Fig S1, Table S1 -S4 from Polymorphic CAG Repeat and Protein Expression of Androgen Receptor Gene in Colorectal Cancer
Authors: Huang Rui , Wang Guiyu , Song Yanni , Wang Feng , Zhu Bing , Tang Qingchao , Liu Zheng , Chen Yinggang , Zhang Qian , Muhammad Shan , Wang Xishan
Published: April 2023

Figure S1: Distribution of CAG repeat length in different centers. Table S1: Clinical and pathological characteristics of patients. Table S2: Comparison of CAG repeat length. Table S3: Comparison of AR expression. Table S4: relationship of CAG repeat length and AR expression in CRC patients.
Supplementary figure 7 from TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-κB and Regresses Mutant EGFR-Associated Human Non–Small Cell Lung Cancers
Authors: Nan Jing , Du Yuping , Chen Xing , Bai Qifeng , Wang Yuxin , Zhang Xinxin , Zhu Ning , Zhang Jing , Hou Jianwen , Wang Qin , Yang Jinbo
Published: April 2023

Combination of TPCA-1 increases sensitivity to gefitinib in TKI insensitive NSCLC.
Supplementary Figure S6 from The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis
Authors: Wang Ni , Rayes Roni F. , Elahi Seyyed Mehdy , Lu Yifan , Hancock Mark A. , Massie Bernard , Rowe Gerald E. , Aomari Hafida , Hossain Sazzad , Durocher Yves , Pinard Maxime , Tabariès Sébastien , Siegel Peter M. , Brodt Pnina
Published: April 2023

Kinetics and specificity of ligand binding to rhIGFBP-1
Supplementary figure 4 from TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-κB and Regresses Mutant EGFR-Associated Human Non–Small Cell Lung Cancers
Authors: Nan Jing , Du Yuping , Chen Xing , Bai Qifeng , Wang Yuxin , Zhang Xinxin , Zhu Ning , Zhang Jing , Hou Jianwen , Wang Qin , Yang Jinbo
Published: April 2023

TPCA-1 inhibits endogenous STAT3 activity with or without exogenous IL6 in NSCLC with EGFR mutation.
Supplementary Figure S3 from The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis
Authors: Wang Ni , Rayes Roni F. , Elahi Seyyed Mehdy , Lu Yifan , Hancock Mark A. , Massie Bernard , Rowe Gerald E. , Aomari Hafida , Hossain Sazzad , Durocher Yves , Pinard Maxime , Tabariès Sébastien , Siegel Peter M. , Brodt Pnina
Published: April 2023

Production and characterization of the IGF-Trap
Supplementary figure 3 from TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-κB and Regresses Mutant EGFR-Associated Human Non–Small Cell Lung Cancers
Authors: Nan Jing , Du Yuping , Chen Xing , Bai Qifeng , Wang Yuxin , Zhang Xinxin , Zhu Ning , Zhang Jing , Hou Jianwen , Wang Qin , Yang Jinbo
Published: April 2023

EGFR silence inhibits STAT3 activation in MDA-MB-231 cells.
Supplementary Figure 8 from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
Authors: Saito Naoya , Sakakibara Keiichi , Sato Takuji , Friedman Jonathan M. , Kufe Donald W. , VonHoff Daniel D. , Kawabe Takumi
Published: April 2023

Supplementary Figure 8: MLN4924 attenuates tumor growth inhibition by CBS9106 in human xenograft model. (A) SCID mice bearing HCT116 tumor xenografts are treated with vehicle (5% GA, p.o. + 10% HBC, s.c.), CBS9106 (250 mg/kg p.o. once per week), MLN4924 (10 or 60 mg/kg s.c. once per week), or combination of CBS9106 and MLN4924 (n = 6-8 mice/group) for two weeks. Data are expressed as the mean {plus minus} SEM. (B) Body weight change is measured during the treatment (means {plus minus} SEM). (C) Tumors are excised at 4 or 24 hours and the levels of Neddylated cullins and CRM1 are measured in the tumor lysates by western blot analysis (n = 3). Data are expressed as the mean {plus minus} SD. V:Vehicle.
Supplementary Figure 5 from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
Authors: Saito Naoya , Sakakibara Keiichi , Sato Takuji , Friedman Jonathan M. , Kufe Donald W. , VonHoff Daniel D. , Kawabe Takumi
Published: April 2023

Supplementary Figure 5: Nuclear export inhibition is canceled by MLN4924 in MM.1S cell. MM.1S cells are treated for 18 hours with CBS9106 (50 nM) and/or MLN4924 (100 nM). (A) Cells are fixed and stained for RanBP1 (cytoplasmic protein, green, left panels) and nucleic acid (Hoechst33342 stain, blue, middle panels). Merged images are shown in the right panels. (B) Cells are fixed and stained for CRM1 (nuclear protein, green, left panels) and nucleic acid (Hoechst33342 stain, blue, middle panels). Merged images are shown in the right panels. The white bar represents 20 microm.
Supplementary Table 1 from Immunotherapy for Hepatoma Using a Dual-Function Vector with Both Immunostimulatory and Pim-3–Silencing Effects
Authors: Guo Qie , Lan Peixiang , Yu Xin , Han Qiuju , Zhang Jian , Tian Zhigang , Zhang Cai
Published: April 2023

PDF - 51K, Table S1. The shRNA and ssRNA template sequences.
Supplemental Figure 6 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
Authors: Theodosakis Nicholas , Held Matthew A. , Marzuka-Alcala Alexander , Meeth Katrina M. , Micevic Goran , Long Georgina V. , Scolyer Richard A. , Stern David F. , Bosenberg Marcus W.
Published: April 2023

Supplemental Figure 6. Vemurafenib effects on cap-dependent translation
Supplemental Figure 4 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
Authors: Theodosakis Nicholas , Held Matthew A. , Marzuka-Alcala Alexander , Meeth Katrina M. , Micevic Goran , Long Georgina V. , Scolyer Richard A. , Stern David F. , Bosenberg Marcus W.
Published: April 2023

Supplemental Figure 4. The effects of MEK inhibitor AZD-6244 on glucose uptake
Supplementary Figure S1 from RNA Interference Using c-Myc–Conjugated Nanoparticles Suppresses Breast and Colorectal Cancer Models
Authors: Tangudu Naveen K. , Verma Vinod K. , Clemons Tristan D. , Beevi Syed S. , Hay Trevor , Mahidhara Ganesh , Raja Meera , Nair Rekha A. , Alexander Liza E. , Patel Anant B. , Jose Jedy , Smith Nicole M. , Zdyrko Bogdan , Bourdoncle Anne , Luzinov Igor , Iyer K. Swaminathan , Clarke Alan R. , Dinesh Kumar Lekha
Published: April 2023

Supplementary Figure S1: TEM, size and zeta potential analysis of the nanoparticles
Supplementary Figure 1 from Targeting c-MYC in Platinum-Resistant Ovarian Cancer
Authors: Reyes-González Jeyshka M. , Armaiz-Peña Guillermo N. , Mangala Lingegowda S. , Valiyeva Fatma , Ivan Cristina , Pradeep Sunila , Echevarría-Vargas Ileabett M. , Rivera-Reyes Adrian , Sood Anil K. , Vivas-Mejía Pablo E.
Published: April 2023

SiRNA-mediated c-MYC silencing in A2780CIS and HEYA8 ovarian cancer cells.
Supplementary Table 2 from Targeted Silencing of MLL5β Inhibits Tumor Growth and Promotes Gamma-Irradiation Sensitization in HPV16/18-Associated Cervical Cancers
Authors: Nin Dawn Sijin , Yew Chow Wenn , Tay Sun Kuie , Deng Lih-Wen
Published: April 2023

Supplementary Table 2: Sequences of primers used
Supplementary figure 5 from A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma
Authors: Mazumdar Tuhina , Byers Lauren A. , Ng Patrick Kwok Shing , Mills Gordon B. , Peng Shaohua , Diao Lixia , Fan You-Hong , Stemke-Hale Katherine , Heymach John V. , Myers Jeffrey N. , Glisson Bonnie S. , Johnson Faye M.
Published: April 2023

Supplementary figure 5. MEK162 and GDC0941 effect on cell cycle
Supplementary Figure S8 from Endostatin Has ATPase Activity, Which Mediates Its Antiangiogenic and Antitumor Activities
Authors: Wang Shan , Lu Xin-an , Liu Peng , Fu Yan , Jia Lin , Zhan Shunli , Luo Yongzhang
Published: April 2023

Supplementary Figure S8. Mutants internalization and HIF1-α
Supplementary Figure S1 from Endostatin Has ATPase Activity, Which Mediates Its Antiangiogenic and Antitumor Activities
Authors: Wang Shan , Lu Xin-an , Liu Peng , Fu Yan , Jia Lin , Zhan Shunli , Luo Yongzhang
Published: April 2023

Supplementary Figure S1. The 3D structure of endostatin and p97
Supplementary Table 4 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Authors: Guzi Timothy J. , Paruch Kamil , Dwyer Michael P. , Labroli Marc , Shanahan Frances , Davis Nicole , Taricani Lorena , Wiswell Derek , Seghezzi Wolfgang , Penaflor Ervin , Bhagwat Bhagyashree , Wang Wei , Gu Danling , Hsieh Yunsheng , Lee Suining , Liu Ming , Parry David
Published: April 2023

Supplementary Table 4 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Supplemental Figure 1 from MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma
Authors: Slotkin Emily K. , Patwardhan Parag P. , Vasudeva Shyamprasad D. , de Stanchina Elisa , Tap William D. , Schwartz Gary K.
Published: April 2023

MLN0128 inhibits pAKT T308 in MPNST and ST8814 cell lines AND Only MLN0128 but not rapamycin induces cleaved PARP in rhabdomyosarcoma cell lines
S5. Validation of target genes within pathways shown to be up-regulated by AZD5363 treatment. from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo
Authors: Ribas Ricardo , Pancholi Sunil , Guest Stephanie K. , Marangoni Elisabetta , Gao Qiong , Thuleau Aurélie , Simigdala Nikiana , Polanska Urszula M. , Campbell Hayley , Rani Aradhana , Liccardi Gianmaria , Johnston Stephen , Davies Barry R. , Dowsett Mitch , Martin Lesley-Ann
Published: April 2023

MCF7 and MCF7-LTED cells lines were cultured in DCC {plus minus} AZD5363 and mRNA analysis performed by RT-qPCR. Error bars represent {plus minus} SEM. *p<0.05; **p<0.01; ***p<0.001. Coloured dots indicate which signalling pathways each gene belongs to.
S3. Temporal effect of the combination of AZD5363 with endocrine therapy on PI3K/mTOR/AKT, ER and cell cycle signalling. from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo
Authors: Ribas Ricardo , Pancholi Sunil , Guest Stephanie K. , Marangoni Elisabetta , Gao Qiong , Thuleau Aurélie , Simigdala Nikiana , Polanska Urszula M. , Campbell Hayley , Rani Aradhana , Liccardi Gianmaria , Johnston Stephen , Davies Barry R. , Dowsett Mitch , Martin Lesley-Ann
Published: April 2023

(A) MCF7 and MCF7-LTED were treated for 1, 8 and 24-hours with the drug combinations indicated (B) T47D, T47D-LTED, ZR75., ZR75-LTED and TamR cell lines were treated for 1-hour as indicated and signalling pathways analysed by immunoblotting. (C) MCF7 and MCF7-LTED cells were treated with the drug combinations indicated for 48-hours and FACS analysis used to measure changes in S-phase . Error bars represent {plus minus} SEM. *p<0.05; **p<0.01; ***p<0.001.
Supplementary Figure 9 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Authors: Guzi Timothy J. , Paruch Kamil , Dwyer Michael P. , Labroli Marc , Shanahan Frances , Davis Nicole , Taricani Lorena , Wiswell Derek , Seghezzi Wolfgang , Penaflor Ervin , Bhagwat Bhagyashree , Wang Wei , Gu Danling , Hsieh Yunsheng , Lee Suining , Liu Ming , Parry David
Published: April 2023

Supplementary Figure 9 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Supplementary Figure 3 from MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide
Authors: Erice Oihane , Smith Michael P. , White Rachel , Goicoechea Ibai , Barriuso Jorge , Jones Chris , Margison Geoffrey P. , Acosta Juan C. , Wellbrock Claudia , Arozarena Imanol
Published: April 2023

Supplementary Figure 3. Western-blot showing the expression levels of the MMR enzymes MSH2, MLH1 and MSH6 in 12 melanoma cell lines.
Sup Figure S2 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood
Authors: Thierry Sylvain , Jdey Wael , Alculumbre Solana , Soumelis Vassili , Noguiez-Hellin Patricia , Dutreix Marie
Published: April 2023

Sup Figure S2.AsiDNA does not induce cell cycle modification: Normal and malignant cells were analyzed by flow cytometry after 12, 24 and 48 hours of treatment with 4.8 Ãƒâ€šÃ,âµM AsiDNA. Results are expressed as the mean of the percentage of cells in each phase from three to four independent experiments: polyploidy (black), G2/M (dark gray), S (light grey), G0/G1 (white), and Sub-G0/G1 (hatched). Error bars represent the standard deviation.
Figure S1 from Quercetin Targets hnRNPA1 to Overcome Enzalutamide Resistance in Prostate Cancer Cells
Authors: Tummala Ramakumar , Lou Wei , Gao Allen C. , Nadiminty Nagalakshmi
Published: April 2023

Chemical structure of quercetin is shown. Effect of quercetin on AR promoter-driven luciferase reporter is shown.
Supplementary Data from Microdose-Induced Drug–DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice
Authors: Zimmermann Maike , Wang Si-Si , Zhang Hongyong , Lin Tzu-yin , Malfatti Michael , Haack Kurt , Ognibene Ted , Yang Hongyuan , Airhart Susan , Turteltaub Kenneth W. , Cimino George D. , Tepper Clifford G. , Drakaki Alexandra , Chamie Karim , de Vere White Ralph , Pan Chong-xian , Henderson Paul T.
Published: April 2023

Chemical structures, patient data, mouse survival curves, additional biomarker data
Supplementary Figures S1-S4 and Legends from Biodistribution and Targeting of Anti-5T4 Antibody–Drug Conjugate Using Fluorescence Molecular Tomography
Authors: Giddabasappa Anand , Gupta Vijay R. , Norberg Rand , Gupta Parul , Spilker Mary E. , Wentland Joann , Rago Brian , Eswaraka Jeetendra , Leal Mauricio , Sapra Puja
Published: April 2023

Supplemental Figure 1: Standard curve of VT680 showing the 3-D quantitation and linearity by FMT imaging; Supplemental Figure 2: Evaluation of VT680 conjugated 5T4-Ab and 5T4-ADC; Supplemental Figure 3: Determination of antibody binding capacity (ABC) and receptor saturation in H1975 and MDA-MB-468 cells by flow cytometry; Supplemental Figure 4: Ex vivo FMT imaging showing the accumulation of 5T4-Ab-VT680, 5T4-ADC-VT680, Isotype control-Ab-VT680 and VT680 alone 48 h post-injection in tumor (A) and liver (B).
Sup Figure 3 from Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC
Authors: Potter Danielle S. , Galvin Melanie , Brown Stewart , Lallo Alice , Hodgkinson Cassandra L. , Blackhall Fiona , Morrow Christopher J. , Dive Caroline
Published: April 2023

Supplementary Figure 3. H524 cytotoxicity
suppl. Tab. 2 from PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway
Authors: Engert Florian , Schneider Cornelius , Weiβ Lilly Magdalena , Probst Marie , Fulda Simone
Published: April 2023

Combination values of PARP inhibitors and chemotherapeutic drugs.
Supplementary Figure S4 from Chikusetsusaponin IVa Butyl Ester (CS-IVa-Be), a Novel IL6R Antagonist, Inhibits IL6/STAT3 Signaling Pathway and Induces Cancer Cell Apoptosis
Authors: Yang Jie , Qian Shihui , Cai Xueting , Lu Wuguang , Hu Chunping , Sun Xiaoyan , Yang Yang , Yu Qiang , Gao S. Paul , Cao Peng
Published: April 2023

The IL-6RÎ±, GP130, pSTAT3 and IL-6 secretion levels in different cells.
Supplementary Tables S2, S3 from Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer
Authors: Gabrielli Brian , Bokhari Fawzi , Ranall Max V. , Oo Zay Yar , Stevenson Alexander J. , Wang Weili , Murrell Melanie , Shaikh Mushfiq , Fallaha Sora , Clarke Daniel , Kelly Madison , Sedelies Karin , Christensen Melinda , McKee Sara , Leggatt Graham , Leo Paul , Skalamera Dubravka , Soyer H. Peter , Gonda Thomas J. , McMillan Nigel A.J.
Published: April 2023

SiRNA screening data validated gene lists
figure S7 from A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity
Authors: Vega Mario I. , Shi Yijiang , Frost Patrick , Huerta-Yepez Sara , Antonio-Andres Gabriela , Hernandez-Pando Rogelio , Lee Jihye , Jung Michael E. , Gera Joseph F. , Lichtenstein Alan
Published: April 2023

Suppl fig 7: A: Examples of IHC staining of normal tissues for DEPTOR expression following daily injection of DMSO or drug 3g (10mg/kg x 21 days); B) Immunoblot analysis of heart tissue for DEPTOR expression
figure S5 from A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity
Authors: Vega Mario I. , Shi Yijiang , Frost Patrick , Huerta-Yepez Sara , Antonio-Andres Gabriela , Hernandez-Pando Rogelio , Lee Jihye , Jung Michael E. , Gera Joseph F. , Lichtenstein Alan
Published: April 2023

Suppl fig 5: A) Mice (4/group) bearing SQ 8226 xenografts were in- Jected IP with DMSO (control (C)) or drug 3g at 20 mg/kg and tumors were excised 24, 48 or 72 hrs later. Tumors were stained for DEPTOR expression. Data are number of DEPTOR-positive cells, mean+/-SD, N=4. *denotes significant decrease versus control, p<0.05. B) Tumor volume in mice (8/group) bearing SQ 8226 xenografts and treated with IP injections of DMSO every day for 26 days (control), drug 3g, 20mg/kg every day for 9 days or drug 3g, 20 mg/kg every other day. The latter treatment schedule (every other day) was day 1,3,5,7,9 and then repeated on day 18, 20, 22 and 24; C) Weights (mean+/-SD) of mice from experiment shown in 'B'
Figure S1, S2, S3, S4 and S5 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer
Authors: Hisamatsu Takeshi , McGuire Michael , Wu Sherry Y. , Rupaimoole Rajesha , Pradeep Sunila , Bayraktar Emine , Noh Kyunghee , Hu Wei , Hansen Jean M. , Lyons Yasmin , Gharpure Kshipra M. , Nagaraja Archana S. , Mangala Lingegowda S. , Mitamura Takashi , Rodriguez-Aguayo Cristian , Eun Young Gyu , Rose Johnathon , Bartholomeusz Geoffrey , Ivan Cristina , Lee Ju-Seog , Matsuo Koji , Frumovitz Michael , Wong Kwong K. , Lopez-Berestein Gabriel , Sood Anil K.
Published: April 2023

Figure S1 shows results od cell viability assays, PRKRA expressions and time course experiments. Figure S2 shows results of heatmap for gene expressions and IPA. Figure S3 shows results of cell viability assay, in vivo experiment. Figure S4 shows the results of experiments for PACT-Dicer or PACT- miR 515-3p interaction. Figure S5 shows the results of experiments for miR-515-3p-AXL interaction.
Figure S2 from A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity
Authors: Vega Mario I. , Shi Yijiang , Frost Patrick , Huerta-Yepez Sara , Antonio-Andres Gabriela , Hernandez-Pando Rogelio , Lee Jihye , Jung Michael E. , Gera Joseph F. , Lichtenstein Alan
Published: April 2023

Suppl fig 2:A) Co-IP between DEPTOR & mTOR in 8226 treated with NSC126405 or 3g; B,C&D) Immunoblot of 8226 cells after 6 hrs incubation with drugs. Relative ex- pression below gels are means of 3 separate experiments; E) Bead pull-down assay to quantify binding of recombinant DEPTOR to mTOR (see Materials & Methods); Lane 1 (furthest to the left) is a control showing anti-FLAG-containing beads (w/o conjugation to mTOR-FLAG) do not non-specifically bind to GST-DEPTOR while mTOR-FLAG-conjugated beads successfully bind GST-DEPTOR (lane 2); Below gel are results from 3 separate experiments showing mean +/-SD percent of control, n=3. DM=DMSO treatment; Drug J007 is a myc IRES inhibitor (6) of similar size to 3g and used as an additional negative control. *=significant decrease from control (DMSO), p<0.05; **=p<0.01. F) Immunoblot after incubation with drug 3g (upper) or NSC126405 (lower).
Figure S1 from A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity
Authors: Vega Mario I. , Shi Yijiang , Frost Patrick , Huerta-Yepez Sara , Antonio-Andres Gabriela , Hernandez-Pando Rogelio , Lee Jihye , Jung Michael E. , Gera Joseph F. , Lichtenstein Alan
Published: April 2023

Supplemental figure 1: A) Hematopoietic colony formation in marrow cells exposed to drug 3g for 14 days (assay as described in (3); Data represent % of control (0uM), mean+/-SD; B)8226 MM cells, PC3 prostate cancer cells, LLC Lewis lung cancer cells and JHH7 hepatocellular cancer cells were incubated for 48 hrs +/- drug 3g at 0 (DMSO), 1 or 2 uM in MTT assays. Data are mean+/-SD, n=3 for MTT cytotoxicity where DMSO controls are 100% survival
Supplementary Tables S10-S15 from A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics
Authors: Quist Jelmar , Mirza Hasan , Cheang Maggie C.U. , Telli Melinda L. , O'Shaughnessy Joyce A. , Lord Christopher J. , Tutt Andrew N.J. , Grigoriadis Anita
Published: April 2023

Supplementary Table S10: Survival analysis in Guy's TNBC and METABRIC TNBC using individual genes. Supplementary Table S11: Survival analysis in Guy's TNBC and METABRIC TNBC using the MC subtypes. Supplementary Table S12: Survival analysis in Sanofi Phase II and Sanofi Phase III using individual genes. Supplementary Table S13: Survival analysis in Sanofi Phase II and Sanofi Phase III using the MC subtypes. Supplementary Table S14: Concordance between the METABRIC-set 15 (MC subtypes) classification and breast cancer subtypes. Supplementary Table S15: Clinicopathological features of the METABRIC-set 15 (MC subtypes) classification in the METABRIC TNBC cohort.
Supplemental Methods; Supplemental Tables S1-S7; and Supplemental Figures S1-S6 from Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1–S Checkpoint
Authors: Zhu Dan , Xu Shuichan , Deyanat-Yazdi Gordafaried , Peng Sophie X. , Barnes Leo A. , Narla Rama Krishna , Tran Tam , Mikolon David , Ning Yuhong , Shi Tao , Jiang Ning , Raymon Heather K. , Riggs Jennifer R. , Boylan John F.
Published: April 2023

SUPPLEMENTAL METHODS â€¢ Correlative analysis of CC-671 sensitivity data with genomic features in the 240 Oncopanel â€¢ Correlative analysis of CC-671 sensitivity data with genomic features or tumor subtypes in 49 breast cancer cell lines â€¢ Molecular of action studies â€¢ Xenograft efficacy studies SUPPLEMENTAL DATA â€¢ Table S1. Primer sequences for PCR â€¢ Table S2. Invitrogen kinase panel data â€¢ Table S3. Growth inhibition (IC50 and AUCR Values) of CC-671 in breast cancer panel â€¢ Table S4. CC-671 effects on cancer cell proliferation, apoptosis, and cell cycle â€¢ Table S5. Cell lines in Oncopanel with mutations in CTNNB1 exon 3 â€¢ Table S6. Correlation between CC-671 IC50 values and mutations in CTNNB1 exon 3 in cancer cell lines â€¢ Table S7. Correlation of CDKN2A and TP53 mutations with sensitivity or resistance to CC-671 in lung and melanoma cell lines from the Oncopanel â€¢ Figure S1. CLK2 knockdown by siRNA reduced phosphorylation of SRp75 in CAL51 cells â€¢ Figure S2. Induction of apoptosis in vivo with a single dose of CC-671 in MDA-MB-231 tumors â€¢ Figure S3. Antitumor activity of CC-671 in CAL51 and MDA-MB-231 TNBC xenograft models â€¢ Figure S4. CC-671 potently and selectively inhibits proliferation and induces apoptosis in cancer cell lines from different anatomic origins â€¢ Figure S5. Cancer cell lines with CTNNB1 exon 3 mutations tend to be more sensitive to CC-671 in Oncopanel, but the correlation does not reach statistical significance â€¢ Figure S6. TTK expression and CC-671 potency correlate with the growth rates (t0) of cell lines in both breast cancer panel and Oncopanel
Table S1-S4 from Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer
Authors: Xu Sen , Yang Zongyuan , Jin Ping , Yang Xin , Li Xiaoting , Wei Xiao , Wang Ya , Long Sixiang , Zhang Taoran , Chen Gang , Sun Chaoyang , Ma Ding , Gao Qinglei
Published: April 2023

Table S1: Summary of ovarian cancer patient clinical data. Table S2:CAFs associated gene signatures. Table S3:ssGSEA scores of fibroblast activation associated gene sets in 31 CAFs and 8 NFs of GSE40595. Table S4:The rank list of pathway scores correlated with the stroma phenotypes performed by GSEA.
Figure S5 from Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer
Authors: Xu Sen , Yang Zongyuan , Jin Ping , Yang Xin , Li Xiaoting , Wei Xiao , Wang Ya , Long Sixiang , Zhang Taoran , Chen Gang , Sun Chaoyang , Ma Ding , Gao Qinglei
Published: April 2023

Metformin-primed CAFs may contribute, at least partly, to the diminished infiltration of M2-like macrophages, related to Figure 6.
Figure S1 from Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer
Authors: Xu Sen , Yang Zongyuan , Jin Ping , Yang Xin , Li Xiaoting , Wei Xiao , Wang Ya , Long Sixiang , Zhang Taoran , Chen Gang , Sun Chaoyang , Ma Ding , Gao Qinglei
Published: April 2023

Identification of the primary CAFs isolated from OC patients, related to Figure 1.
Supplementary Tables 1-4 from Clinical Application of Circulating Tumor DNA in the Genetic Analysis of Patients with Advanced GIST
Authors: Xu Hao , Chen Liang , Shao Yang , Zhu Dongqin , Zhi Xiaofei , Zhang Qiang , Li Fengyuan , Xu Jianghao , Liu Xisheng , Xu Zekuan
Published: April 2023

Supplementary table 1 Univariate analysis of influence factors of concordance between ctDNA and tissue DNA detections; Supplementary table 2 Concordance analysis between ctDNA and tissue DNA detections in genetic analysis (Tumor size>10cm, n=23); Supplementary table 3 Concordance analysis between ctDNA and tissue DNA detections in genetic analysis (Ki-67>5%, n=19); Supplementary table 4 Univariate analysis of influence factors of prognosis (Log-rank Test)
Supplemental figure 5. Combined PIM/MEK inhibition restores sensitivity to AZD1208 in NF1 knock out cell lines from PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma
Authors: Brunen Diede , de Vries Romy C. , Lieftink Cor , Beijersbergen Roderick L. , Bernards René
Published: April 2023

(A-F) The indicated cell lines were plated in 6-well plates and treated with AZD1208, cobimetinib, MK2206 or the combination. Drug-containing medium was refreshed every 3 days. Cells were fixed, stained, and scanned when untreated wells reached confluency (n=3).
Supplemental figure 3. gRNAs targeting essential genes are depleted in time from PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma
Authors: Brunen Diede , de Vries Romy C. , Lieftink Cor , Beijersbergen Roderick L. , Bernards René
Published: April 2023

The x-axis depicts the average number of sequencing reads in the untreated/T0 samples. The y-axis depicts the log2 fold change in abundance of gRNAs in the untreated versus T0 population. gRNAs targeting essential genes are depicted in red, gRNAs targeting non-essential genes are depicted in blue, and all other gRNAs in the library are depicted in black
Table S1 from The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression
Authors: Wallez Yann , Dunlop Charles R. , Johnson Timothy Isaac , Koh Siang-Boon , Fornari Chiara , Yates James W.T. , Bernaldo de Quirós Fernández Sandra , Lau Alan , Richards Frances M. , Jodrell Duncan I.
Published: April 2023

Genetic alterations likely to sensitize to ATR inhibition in the human PDAC cell lines
Supplementary Figure S2 from Suppression of Prostate Cancer Pathogenesis Using an MDA-9/Syntenin (SDCBP) PDZ1 Small-Molecule Inhibitor
Authors: Das Swadesh K. , Kegelman Timothy P. , Pradhan Anjan K. , Shen Xue-Ning , Bhoopathi Praveen , Talukdar Sarmistha , Maji Santanu , Sarkar Devanand , Emdad Luni , Fisher Paul B.
Published: April 2023

Effects of PDZ1i on various tumor-derived pro-angiogenic factors
Figure S1 from Specific RITA Modification Produces Hyperselective Cytotoxicity While Maintaining In Vivo Antitumor Efficacy
Authors: Peyser Brian D. , Hermone Ann , Salamoun Joseph M. , Burnett James C. , Hollingshead Melinda G. , McGrath Connor F. , Gussio Rick , Wipf Peter
Published: April 2023

Robust SI calculation removes spurious results.
Supplementary Figure S1 from Suppression of Prostate Cancer Pathogenesis Using an MDA-9/Syntenin (SDCBP) PDZ1 Small-Molecule Inhibitor
Authors: Das Swadesh K. , Kegelman Timothy P. , Pradhan Anjan K. , Shen Xue-Ning , Bhoopathi Praveen , Talukdar Sarmistha , Maji Santanu , Sarkar Devanand , Emdad Luni , Fisher Paul B.
Published: April 2023

PDZ1i does not affect the IL-6 mediated IGF-1R/STAT3 signaling axis.
Supplementary tables S1-2, Supplementary figures S1-6, Captions for supplementary videos 1 to 7 from Multiplex Three-Dimensional Mapping of Macromolecular Drug Distribution in the Tumor Microenvironment
Authors: Lee Steve Seung-Young , Bindokas Vytautas P. , Kron Stephen J.
Published: April 2023

Supplementary Table S1. Fluorescent antibody conjugation; Supplementary Table S2. Fiji macros for 3D image processing and analysis; Supplementary Figure S1. Comparison of 2D and 3D images of anti-PD-L1 antibody drug distribution in tumor at 12 h post injection; Supplementary Figure S2. 3D spatial pharmacokinetics of anti-PD-L1 antibody in tumor macrosections; Supplementary Figure S3. Fluorescence calibration curve for anti-PD-L1 antibody concentration in plasma; Supplementary Figure S4. Optimizing fixation and immunostaining conditions for 3D imaging macromolecular drug distribution in 400 Î¼m thick tumor macrosections; Supplementary Figure S5. 3D mapping of different types of microvessels and their permeability with regards to anti-PD-L1 antibody drug penetration into tumor. Supplementary Figure S6. 3D visualization of macromolecular drug distribution in tumors.
Supplementary Figure 2 from The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models
Authors: Handle Florian , Puhr Martin , Schaefer Georg , Lorito Nicla , Hoefer Julia , Gruber Martina , Guggenberger Fabian , Santer Frédéric R. , Marques Rute B. , van Weerden Wytske M. , Claessens Frank , Erb Holger H.H. , Culig Zoran
Published: April 2023

The STAT3 inhibitor galiellalactone inhibits the transcriptional activity of STAT3 without reducing its phosphorylation